APOA1 and coronary atherosclerosis: Due to the small number of patients, the findings may be viewed as exploratory, but they demonstrate the proof-of-concept that recombinant apoA-I antibodies derived from the phage display library against CAD HDL particles may be used to improve the estimation of the risk of coronary atherosclerosis.